ERA

Download the full-sized PDF of The pharmaceutical industry’s willingness-to-sell targeted chemotherapy for incurable solid cancersDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3834W

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

The pharmaceutical industry’s willingness-to-sell targeted chemotherapy for incurable solid cancers Open Access

Descriptions

Other title
Subject/Keyword
medical oncology
systematic review
industry
health finance
pharmacoeconomics
targeted therapy
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Conter, Henry J
Supervisor and department
Menon, Devidas (Department of Public Health Sciences)
Examining committee member and department
Butts, Charles (Department of Oncology)
Jhangri, Gian (Department of Public Health Sciences)
Klarenbach, Scott (Division of Nephrology)
McCabe, Chris (Department of Public Health Sciences)
Department
School of Public Health Sciences
Specialization
Health Technology Assessment
Date accepted
2012-12-17T15:35:15Z
Graduation date
2013-06
Degree
Master of Science
Degree level
Master's
Abstract
How the costs of research and its associated risks contribute to a minimum price that would support continued private pharmaceutical investment is unclear. We employed a linear cost-volume-revenue breakeven analysis to equate initial capital investment and risk, and its associated post-drug-approval revenue. A decision-tree analytic model was utilized to define the relationships between investment events, outcomes, and risk. A systematic review was employed to determine the model inputs. In oncology, the minimum revenue required to support R&D is $4.34 billion USD to $5.21 billion USD. The strategy undertaken to develop a new drug can reduce the associated revenue to $2.77 - $3.49 billion USD. Utilizing multi-tumour phase I clinical trials may allow for $853 million USD to $983 million USD in additional reductions. The minimum required return on investment varies with estimates for cost of capital and the approach a firm uses when developing novel therapeutics.
Language
English
DOI
doi:10.7939/R3834W
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-05-01T01:43:49.013+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 776547
Last modified: 2015:10:12 12:55:19-06:00
Filename: Conter_Henry_winter 2013.pdf
Original checksum: 3d0699afab60fe56d5a29d9460ee2c32
Well formed: false
Valid: false
Status message: Invalid page tree node offset=641676
Status message: Unexpected error in findFonts java.lang.ClassCastException: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject cannot be cast to edu.harvard.hul.ois.jhove.module.pdf.PdfDictionary offset=3090
Page count: 75
Activity of users you follow
User Activity Date